PI与PE方案治疗小细胞肺癌疗效观察  

Clinical effects of PI and PE in treatment of small cell lun Cancer

作　　者：王青蓝[1] 郭本成[1] 邹淑芬[1] 

机构地区：[1]山东省莱芜市人民医院内二科,271100

出　　处：《中国实用医药》2007年第32期37-38,共2页China Practical Medicine

摘　　要：目的研究DDP+CPT-11及DDP+VP-16两种方案分别治疗小细胞肺癌的临床疗效、不良反应和生存质量。方法PI组30例患者,DDP60mg/m2静脉滴注,d1;依利替康60mg/m2,静脉滴注,d1、8、15。PE组20例患者,DDP60mg/m2,静脉滴注,d1;Vp-16100mg/m2静脉滴注,d1～5。两种方案均为28d为1个周期,连续治疗2～3个周期。结果PI组1年生存率为58.2%,2年生存率为18.7%;PE组1年生存率为37.5%,2年生存率为6.3%。结论PI组临床疗效、生存质量优于PE组,是临床较好的治疗方案。Objective To study the clinical efficacies,adverse effects and quality of life of the two regimens DDP+CPT-11 and DDP+VP-16 in treatment of small cell lung cancer.Methods There are 30 cases in the PI Group,and DDP of 60 mg/m2 is given iv on the first day;Irinotecan of 60 mg/m2 is given on the first day,the 8th day and the 15th day,iv.There are 20 cases in the PE Group and DDP of 60 mg/m2 is given iv on the first day;VP-16 of 100 mg/m2 is given for 5 days,iv.One cycle of the two regimens is 28 days and the efficacies will be evaluated after treating 2～3 cycles.Results PI group survival rate are respectively 58.2% and 18.7% for one and two years. PE group survival rate are respectively 37.5% and 6.3% for one and two years.Conclusion We find the PI Group is better than the PE Group in respect of clinical efficacies and quality of life and it proves to be a better treatment regimens clinically.

关 键 词：小细胞肺癌/药物疗法 顺铂/投药和剂量 依利替康/投药和剂量 

分 类 号：R734.2[医药卫生—肿瘤]